| $385M | ||
| $350M | ||
| $215M | ||
| $82M | ||
| $76M | ||
| $62M |
Buys | $49,311 | 10 | 100 |
Sells | $0 | 0 | 0 |
| Bitterman Robert J | Chairman, Pres & CEO | 8 | $38,711 | 0 | $0 | $38,711 |
| Ferrara Robert L | director | 2 | $10,600 | 0 | $0 | $10,600 |
Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States. It offers INTASYL therapeutic platform focuses on targeting tumor and immune cells by regulating genes of the immune system. The company develops PH-762 that activates immune cells to recognize and kill cancer cells by reducing the expression of the checkpoint protein PD-1 for immunotherapy in adoptive cell transfer (ACT); PH-894 that silences the epigenetic protein BRD4, which is an intracellular regulator of gene expression for use in ACT; and PH-804 that targets the suppressive immune receptor TIGIT, which is a checkpoint protein present on T cells and natural killer cells for use in ACT. It has collaborations with AgonOx Inc. on clinical development of novel T cell-based cancer immunotherapies. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is headquartered in Marlborough, Massachusetts.
Over the last 12 months, insiders at Phio Pharmaceuticals Corp. have bought $49,311 and sold $0 worth of Phio Pharmaceuticals Corp. stock.
On average, over the past 5 years, insiders at Phio Pharmaceuticals Corp. have bought $16,588 and sold $0 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Bitterman Robert J (Chairman, Pres & CEO) — $38,711. Ferrara Robert L (director) — $10,600.
The last purchase of 5,000 shares for transaction amount of $5,150 was made by Bitterman Robert J (Chairman, Pres. & CEO) on 2025‑12‑31.
| 2025-12-31 | Bitterman Robert J | Chairman, Pres. & CEO | 5,000 0.0469% | $1.03 | $5,150 | +3.81% | ||
| 2025-12-23 | Bitterman Robert J | Chairman, Pres. & CEO | 5,000 0.0431% | $1.02 | $5,100 | +4.85% | ||
| 2025-11-21 | Bitterman Robert J | Chairman, Pres. & CEO | 5,000 0.1061% | $1.14 | $5,700 | 0.00% | ||
| 2025-11-18 | Bitterman Robert J | Chairman, Pres. & CEO | 5,000 0.1042% | $1.27 | $6,350 | -11.81% | ||
| 2025-06-10 | Bitterman Robert J | Chairman, Pres & CEO | 2,000 0.0408% | $2.42 | $4,840 | -17.41% | ||
| 2025-06-10 | Ferrara Robert L | director | 2,500 0.051% | $2.42 | $6,050 | -17.41% | ||
| 2025-06-09 | Bitterman Robert J | Chairman, Pres & CEO | 1,500 0.0308% | $2.75 | $4,125 | -26.88% | ||
| 2025-05-22 | Bitterman Robert J | Chairman, Pres & CEO | 1,200 0.0242% | $1.78 | $2,136 | +11.14% | ||
| 2025-05-21 | Bitterman Robert J | Chairman, Pres & CEO | 3,000 0.0618% | $1.77 | $5,310 | +13.97% | ||
| 2025-05-20 | Ferrara Robert L | director | 2,500 0.0518% | $1.82 | $4,550 | +11.48% | ||
| 2024-06-07 | Bitterman Robert J | President & CEO | 1,000 0.0216% | $0.74 | $740 | -60.95% | ||
| 2024-06-06 | Bitterman Robert J | President & CEO | 1,000 0.0218% | $0.75 | $750 | -61.19% | ||
| 2024-02-26 | Bitterman Robert J | President & CEO | 2,500 0.0539% | $0.91 | $2,275 | -60.89% | ||
| 2023-07-01 | Bitterman Robert J | President & CEO | 1,000 0.0866% | $2.84 | $2,840 | -48.79% | ||
| 2023-06-30 | Bitterman Robert J | President & CEO | 1,000 0.0879% | $2.88 | $2,880 | -67.89% | ||
| 2023-06-14 | Ferrara Robert L | director | 2,000 0.1723% | $3.10 | $6,200 | -69.59% | ||
| 2022-12-14 | Bitterman Robert J | Interim Executive Chairman | 2,000 0.015% | $0.39 | $780 | -34.24% | ||
| 2022-12-07 | Bitterman Robert J | Interim Executive Chairman | 2,000 0.0149% | $0.39 | $780 | -31.77% | ||
| 2022-12-05 | Bitterman Robert J | Interim Executive Chairman | 2,000 0.0156% | $0.43 | $860 | -34.98% | ||
| 2022-12-02 | Ferrara Robert L | director | 5,000 0.0377% | $0.41 | $2,041 | -32.25% |
| Bitterman Robert J | Chairman, Pres. & CEO | 291421 2.7073% | $352,619.41 | 22 | 0 | <0.0001% |
| Ferrara Robert L | director | 15666 0.1455% | $18,955.86 | 6 | 0 | <0.0001% |
| Galena Biopharma, Inc. | 10 percent owner | 32393095 300.9272% | $39.2M | 0 | 3 | |
| Advanced RNA Technologies, LLC | 1221723 11.3496% | $1.48M | 1 | 0 | ||
| Eliseev Alexey | Chief Business Officer | 950312 8.8283% | $1.15M | 0 | 4 | |
| CAUWENBERGH GEERT | President & CEO | 142583 1.3246% | $172,525.43 | 60 | 0 | |
| Dispersyn Gerrit | President & CEO | 95281 0.8851% | $115,290.01 | 5 | 0 | <0.0001% |
| Lockshin Curtis | director | 1000 0.0093% | $1,210.00 | 1 | 0 |
$17,168,388 | 54 | -43.55% | $10.61M | |
$448,545 | 49 | -21.85% | $17.86M | |
$6,204,522 | 45 | 1.91% | $17.51M | |
$1,616,354 | 20 | -12.22% | $11.42M | |
$114,619,342 | 20 | -7.41% | $15.87M | |
$6,733,543 | 17 | -19.02% | $10.53M | |
Phio Pharmaceuticals Corp. (PHIO) | $49,590 | 16 | -37.31% | $13.02M |
$25,487,383 | 15 | -4.37% | $14.15M | |
$79,536,861 | 15 | -6.81% | $11.08M | |
$1,246,170 | 12 | 65.67% | $11.3M | |
$4,146,041 | 11 | -40.86% | $12.31M | |
$13,486,672 | 11 | 82.26% | $18.41M | |
$20,759,738 | 11 | -44.68% | $9.84M | |
$206,317 | 7 | -29.23% | $14.1M | |
$2,060,158 | 5 | -21.35% | $10.56M | |
$10,105,079 | 5 | -26.86% | $18.35M | |
$9,828 | 3 | -32.17% | $13.09M | |
$14,530 | 3 | 62.23% | $12.1M | |
$500,000 | 1 | -22.94% | $14.57M |
| Increased Positions | 13 | +162.5% | 176,181 | +93.47% |
| Decreased Positions | 2 | -25% | 819 | -0.43% |
| New Positions | 8 | New | 123,821 | New |
| Sold Out Positions | 2 | Sold Out | 819 | Sold Out |
| Total Postitions | 19 | +137.5% | 363,848 | +93.04% |
| Vanguard Group Inc | $96.00 | 0.8% | 87,628 | +38,963 | +80.06% | 2025-09-30 |
| Geode Capital Management, Llc | $63.00 | 0.53% | 57,906 | +212 | +0.37% | 2025-09-30 |
| Cetera Investment Advisers | $37.00 | 0.31% | 33,500 | +1,000 | +3.08% | 2025-09-30 |
| Morgan Stanley | $7.00 | 0.06% | 6,000 | 0 | 0% | 2025-09-30 |
| Bank Of America Corp /De/ | $2.00 | 0.01% | 1,400 | +1,354 | +2,943.48% | 2025-09-30 |
| Sbi Securities Co., Ltd. | $1.00 | 0.01% | 1,101 | -808 | -42.33% | 2025-09-30 |
| Bnp Paribas Financial Markets | $0 | <0.01% | 413 | +413 | New | 2025-09-30 |
| Tower Research Capital Llc (Trc) | $0 | <0.01% | 406 | +406 | New | 2025-09-30 |
| Assetmark, Inc | $0 | <0.01% | 110 | 0 | 0% | 2025-09-30 |
| Ubs Group Ag | $0 | 0% | 13 | +13 | New | 2025-09-30 |